Oppenheimer Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $104

Wedbush analyst Andreas Argyrides maintains $MoonLake Immunotherapeutics(MLTX.US)$ with a buy rating, and adjusts the target price from $92 to $104.According to TipRanks data, the analyst has a succes

Futu NewsJun 25 20:31 · Ratings

Express News | MoonLake Immunotherapeutics : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $104

BreakingsJun 25 20:24

MoonLake Immunotherap Initiated at Outperform by Oppenheimer

MoonLake Immunotherap Initiated at Outperform by Oppenheimer

Dow JonesJun 25 17:58

MoonLake Immunotherap Price Target Announced at $104.00/Share by Oppenheimer

MoonLake Immunotherap Price Target Announced at $104.00/Share by Oppenheimer

Dow JonesJun 25 17:58

Oppenheimer Initiates Coverage On MoonLake With Outperform Rating, Announces Price Target of $104

Oppenheimer analyst Andreas Argyrides initiates coverage on MoonLake with a Outperform rating and announces Price Target of $104.

Analyst UpgradesJun 25 17:48

Psoriasis Market to Register Incremental Growth by 2034, Predicts DelveInsight | Key Companies - AnaptysBio, Nimbus Lakshmi, Takeda, MoonLake Immunotherapeutics, Bristol-Myers Squibb, Amgen, Dermavant Sciences

DelveInsight's analysts estimate that the psoriasis market is poised to show significant growth, mainly attributed to increasing prevalence, recent drug approvals, and anticipated launch of novel the

PR NewswireJun 25 05:31